Search

Displaying results 1901 - 1910 of 3020 in total
  1. Drug

    Caprospinol

    go.drugbank.com/drugs/DB05263
    Experimental

    Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.

  2. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    Tasonermin is recombinant soluble form tumor necrosis factor α produced via Escherichia coli cell culture. It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent remov...

  3. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]

  4. Drug

    TU-100

    go.drugbank.com/drugs/DB12467
    Investigational

    TU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.

  5. Drug

    Palazestrant

    go.drugbank.com/drugs/DB18971
    Investigational

    Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).

  6. Drug

    IP-2018

    go.drugbank.com/drugs/DB19049
    Investigational

    IP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients).

  7. Drug

    GT-AS

    go.drugbank.com/drugs/DB17883
    Experimental

    GT-AS recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP.

  8. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    [A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]

  9. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.

  10. Drug

    Lucitanib

    go.drugbank.com/drugs/DB11845
    Investigational

    Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.